It has been reported that large genomic deletions in the MLH1 and MSH2 genes are a frequent cause of Lynch syndrome in certain populations.
INTRODUCTION

Hereditary Nonpolyposis Colorectal Cancer syndrome (HNPCC), or Lynch
Syndrome (MIM# 120435), is probably the most common form of inherited colorectal cancer, accounting for 1%-5% of cases (1) 
Reverse Transcription PCR (RT-PCR)
All the alterations detected by MLPA were confirmed by RT-PCR. Three microliters of total RNA were used to synthesize complementary DNA (cDNA) with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using random primers. RT-PCR was performed with specific primers designed for the coding sequences flanking the putative mutation. To confirm deletions, short amplicons from RT-PCR were sequenced with the following primers:
Exon 4-8 deletion: Forward in exon 3: 5´-gttggagttgggtatgtggatt -3´ and Reverse in exon 9: 5´-tgttgactgcatcttcttttcc -3´.
Exon 7 deletion: Forward in exon 6: 5´-tgctgaataagtgtaaaacccc -3´ and Reverse in exon 8: 5´-ggagaagtcagaacgaagatcag -3´.
Immunohistochemical (IHC) and tumor microsatellite instability (MSI) testing.
IHC staining for MLH1, MSH2 and MSH6 genes in tissue from at least one individual of the genomic rearrangement families was analyzed by a pathologist in the General Yagüe Hospital, Burgos (Spain).
Paraffin-embedded tumors from these cases were received in our laboratory for MSI study. Paired colon tumor tissues and normal tissues were microdissected and DNA extracted using the DNAeasy Tissue kit (Qiagen). A fluorescence multiplex polymerase chain reaction to amplify BAT25, BAT26, D2S123, D5S346 and D17S250 was carried out as described before (14, 15) with slight modifications. Fluorescently labeled PCR products were detected using the ABI as microsatellite stable if none of the five markers showed instability, as MSIlow if one of the five markers showed instability, and as MSI-high if two or more markers showed instability (14).
Breakpoint characterization
A CGH array strategy was done to confirm the deletions identified by MLPA and to identify the location of deletion breakpoints.
One positive sample, from each different family with a rearrangement, was tested by a Human Array CGH 44K specially designed by Nimgenetics for coverage of chromosome 2: 47419322-47580004 (NCBI 36).
Based on the information obtained from the CGH array, primers were designed spanning the putative breakpoints for each case and used in long-range PCR.
Haplotype analysis
Index cases and their relatives were genotyped with 8 microsatellite polymorphic markers surrounding the MSH2 gene and 2 SNPs in the MSH2 gene. As controls, 96 unrelated DNA samples from the general population of Castilla y Leon (National DNA Bank) were also genotyped, and allele frequencies were estimated.
The ten markers used were localized in a ~3.6 Mb region encompassing MSH2 (locus order: cen-D2S123-D2S1248-D2S1247-Clen30-rs3771278-rs2162123-D2S2227-D2S391-Clen27-D2S119-tel) on chromosome 2: 47419322-47580004. 
Phenotypic Characterization
Genealogical data and phenotype characteristics (gender, age at onset, cancer history and characteristic feature of tumors) were evaluated in all rearrangement carrier families.
Statistical Method
Comparisons between mismatch repair mutation types (point mutations versus deletions) in the MSH2 gene were assessed using the web resource GraphPad
Sofware.
The variables related to the proband family members included type and number of colorectal cancer, endometrial cancer and/or other Lynch syndrome related cancers and the corresponding ages of diagnosis.
The number and type of cancers were treated as a categorical variable.
Categorical data were reported as absolute values (n), relative frequencies (%), while groups were compared by analyzing a 2x2 contingency 
RESULTS
Molecular mutation identification
A total of 24 families with a pathogenic germline mutation were detected in MSH2, MLH1, and MSH6 by combined HA_CAE-MLPA analysis.
Clinicopathological features, molecular findings of the index patients and sample numbers are listed in Table 1 . Twelve of these families (50%) are carriers of a novel mutation. Seven of them (29.2%) have a rearrangement, all in MSH2. Two new rearrangements encompassing exon 7 and exons 4-8 deletions were detected in three and four non-related families respectively.
Identification of the MSH2 recurrent mutations
One family had previously been detected with exon 7 deletion and three families and VA134) were studied for exons 4-8 deletion; and 3 families (VA4, VA169 and VA247) for exon 7 deletion. Table 1 shows that 58 patients (19% of our tested population) were analyzed for a rearrangement, 60% of whom are carriers.
A high frequency of MSH2 4-8 exons deletion was observed in MSH2 mutation carrier families, which accounted for more than 26% (4/15).
In total, 33 probands were analyzed, 22 of which are carriers and 11 are not IHQ and IMS were analyzed in two families and both presented no-staining of the MSH2 protein and MSI-H (See Table 1 ).
Breakpoint identification
A customized 4x44 Agilent platform was used to map somatic rearrangements (Designed by NimGenetics, Spain). The aCGH assay provides a prediction of rearrangement breakpoints for the convenient design of primers and sequencing. 822 oligonucleotide probes were used to cover MSH2. A median distance between non-overlapping array probes of 500 bp was obtained. sequences in all cases (ID proband in Table 1 ) is suggestive of a founder mutation, since a frequently recurring recombination event would be likely to result in at least a few single-nucleotide differences.
Haplotype analysis
Haplotype analysis was performed to confirm the common genetic origin of the deletion rearrangements (Figure 2) . Most of the positive families for the deletion are from a small area in Castilla y León (in central of Spain), ancestors of families carrying the exon 4-8 deletion came from Valle de las Navas and exon 7 deletion ancestors came from Lerma, both in the province of Burgos.
A shared haplotype was observed cosegregating with the mutation (Figure 2) which was absent in non-carriers of these families. It provides evidence for a common ancestry among these families. 96 unrelated samples were also genotyped as controls and allele frequencies were estimated; these are also shown in figures 2.1 and 2.2.
Screening of founder rearrangement deletion in MSH2
A PCR test was designed to screen these deletions in first degree relatives. A routine PCR procedure was optimized. Three primer sequences were used: one forward and two reverse. The product is a multiplex PCR with the presence of one band in the wild type and two bands in deletion carrier samples (Figure 3 This procedure is faster, cheaper and easier than MLPA.
Genotype-Phenotype correlation
Taking into account the fact that 62.5% of mutations we have found are in MSH2, largely due to the existence of two recurrent mutations in this gene which represent approximately half the mutations in MSH2; we have correlated the type of mutation (punctual or rearrangement) with the occurrence of extracolonic tumors and the age at diagnosis ( Table 2 ).
The results of table 2 show no differences between the two groups in the number of tumors developed (p=1.0000) or the age at diagnosis, using the threshold of 50 years (p=1.0000); unlike the tumor type, where the prevalence of endometrial and urinary system tumors are higher in founder mutation carriers than point mutation carriers (p=0.47279, p=0.1247).
On the other hand, it must be emphasized that the median age at onset is different in both groups; 46.7 years versus 40.67 years in CRC males and 50 years versus 33 years in CRC females. These data, however, were not statistically significant.
DISCUSSION
Lynch syndrome is a heterogeneous disorder with respect to its molecular basis, as well as its phenotypic expression. 
Here, 160 families were screened using a combined method previously published by our group (12). The overall mutation detection rate in our study is 15% (24 positive families out of 160).
We have found 8 MLH1 mutation carrier families (Table 1) , 3 of which have the c.306+5G>A mutation, which has been described as a founder mutation in Spain, and our group has participated in the work (17) . Two truncated mutations in exon 1 at MLH1 are novel, both appearing in a proband with colon cancer before 50 years of age; while the MLH1_01285 mutation has being described by us before (18) .
Only one family is an MSH6 mutation carrier, this is a novel truncated variant.
The carrier shows a late onset endometrial cancer with absence of any staining of the MSH6 protein and MSS tumor. Similar results have been reported in several studies (19) .
The higher rate of mutations in this study appears in the MSH2 gene (nearly double that in MLH1); this is probably due to the high number of recurrent mutations in this gene.
Two mutations which affect the splicing are reported here and which have been described by us in LOVD. The c.1661G>A mutation is present in family VA6, which is a large family, and we have studied 44 members, of which 18 are carriers ( Table 1) The most important evidence in our study is a big deletion that includes five exons in the MSH2 gene, an in-frame mutation that produces a shorter protein and appears in four non-related Amsterdam criteria fulfilled families.
The study of the breakpoint in index cases of each of the four families and the haplotype analyzed confirms the same mutation in all families (Figure 2. 2).
We identified that another Alu repeat event that was involved in the exon 4-8 deletion (Figure 2 simpler, faster and cheaper method to detect these mutations. Thus, our sample study protocol could be changed and a pre-screening of founder mutations can be started.
We have performed a multiplex PCR (Figure 3 ) that is cheaper than the MLPA method. Table 2 describes the cancer types in affected carriers and the average age of onset. Most of them developed colon cancer before the age of 45, and the women developed endometrial cancer before the age of 50.
Our data indicate that the anticipation phenomenon is associated with exons 4-8 MSH2 deletion. This is a subjective observation based on evidence from the age of onset and an exhibition of a more aggressive disease severity (number of cancers/tumors or the stage of the tumor) over successive generations (Figure 2. 2).
The anticipation phenomenon has been described in other syndromes (22) . The presence of anticipation in HNPCC is more controversial and some reports provide significant evidence that MHL1 mutations, in particular, may be associated with anticipation (23). Our data suggest that MSH2 deletions may well be associated with anticipation effects. The median age at colon cancer diagnosis was 44 years in the four families (Table 2 ), but in family VA20, we observed that the difference at onset over two generations was 20 years. In family VA17, the number of cancers increased over the generations. promoter and exon 9, and it is possible that these sequences mediate the recombination observed in this gene (24, 25) .
Estimating the age of founder mutations is generally an inexact task (26) . It was therefore impossible to estimate whether all our founder carrier families share the same haplotype. The fraction of haplotype can be inadequate for recombination events as we have a small number of carrier families and these show a short genealogy length. The evidence suggests that the origin of these mutations is a recent event.
Given the high proportion of rearrangements, we have evaluated the phenotype in MSH2 mutation carriers. A more severe phenotype (more different tumors, less onset, etc.) in rearrangement carriers was expected (25), but differences were not found. We only noticed a less primary CRC tumor onset in rearrangement carriers than in other MSH2 mutations carriers.
We detected rearrangements more often in families with endometrial or urinary cancer. These data are similar to those published by Geray et al. (27) . A possible explanation could be that both rearrangements occur in the MSH2 gene and both are founder mutations in our population.
The differences found are not statistically significant, and this does not allow us to orient the diagnosis based on mutation type (punctual or rearrangement) in clinicopathologically suspect patients of MSH2 mutation.
In conclusion, we have provided genetic evidence that the exon 7 deletion and exons 4-8 deletion are both pathogenic founder mutations involved in causing HNPCC in a territory in central Spain. Our data show that large genomic rearrangements occur in these genes with a high frequency and emphasize the need to incorporate techniques to routinely detect them. This should facilitate 
